Lilly restructures in preparation for Alzheimer’s drug launch
2021 may go down in history as the year when everything changed in Alzheimer’s disease.
Following the approval of Biogen’s Aduhelm (aducanumab) in June, Eli Lilly has created a new business unit, Lilly Neuroscience, to shepherd the company’s portfolio in pain and neurodegeneration.
This includes the company’s potential drug for Alzheimer’s disease, donanemab, which received breakthrough therapy designation in June based on its phase 2 data.
Bio-Medicines will actually split in two: Lilly Neuroscience will be overseen by Anne White, who has guided Lilly Oncology for several years, and Lilly Immunology will be led by current Lilly Bio-Medicines head, Patrik Jonsson.
Jacob (Jake) Van Naarden, currently chief executive officer of Loxo Oncology, will bring together and lead Loxo and Lilly Oncology, and join Lilly's executive committee.
Although Alzheimer’s disease is the sixth leading cause of death in the US, until now there were no therapies that treated the course of the disease. Biogen’s Aduhelm and Lilly’s donanemab are the first new drugs for more than two decades in the therapy area, but they are not without controversy.
Read more: http://www.pmlive.com/pharma_news/lilly_restructures_in_preparation_for_alzheimers_drug_launch_1375423
Following the approval of Biogen’s Aduhelm (aducanumab) in June, Eli Lilly has created a new business unit, Lilly Neuroscience, to shepherd the company’s portfolio in pain and neurodegeneration.
This includes the company’s potential drug for Alzheimer’s disease, donanemab, which received breakthrough therapy designation in June based on its phase 2 data.
Bio-Medicines will actually split in two: Lilly Neuroscience will be overseen by Anne White, who has guided Lilly Oncology for several years, and Lilly Immunology will be led by current Lilly Bio-Medicines head, Patrik Jonsson.
Jacob (Jake) Van Naarden, currently chief executive officer of Loxo Oncology, will bring together and lead Loxo and Lilly Oncology, and join Lilly's executive committee.
Although Alzheimer’s disease is the sixth leading cause of death in the US, until now there were no therapies that treated the course of the disease. Biogen’s Aduhelm and Lilly’s donanemab are the first new drugs for more than two decades in the therapy area, but they are not without controversy.
Read more: http://www.pmlive.com/pharma_news/lilly_restructures_in_preparation_for_alzheimers_drug_launch_1375423
